Structure Therapeutics, Inc. Share Price

NASDAQ: GPCR

Mid Cap

$20.89

+0.01

(+0.05%)

as on September 13, 2025 at 1:29 am IST

$₹

Structure Therapeutics, Inc. Stock Performance

as on September 13, 2025 at 1:29 am IST

Day's Low
Day's High
$20.29
Day's Price Range
$21.47
$20.89
2.87%
Downside
2.78%
Upside
52 Week's Low
52 Week's High
$13.22
52-Week Price Range
$45.37
$20.89
36.72%
Downside
117.19%
Upside

Structure Therapeutics, Inc. share price movements today

Previous Close: $20.88
Open: $20.76
Volume: 1.4M
Day's Low - High: $20.29 - $21.47
52 Week Low - High: $13.22 - $45.37

Structure Therapeutics, Inc. Historical Returns

1 Month Return: + 9.13 %
3 Month Return: -3.55 %
1 Year Return: -48.8 %
3 Year Return: 0 %
5 Year Return: 0 %

Structure Therapeutics, Inc. Stock Fundamentals & Key Indicators

Check Structure Therapeutics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.2B

EPS (TTM)

-1.2491

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

P/B Ratio

PEG Ratio

EBITDA

-218.6M

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

251984100.00%

Structure Therapeutics, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Structure Therapeutics, Inc. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Structure Therapeutics, Inc.	BUY	$1.2B	NA	NA	0.00%
Alnylam Pharmaceuticals, Inc.	BUY	$61.1B	280.5%	-505.15	-12.96%
Beone Medicines Ltd	NA	$37.7B	NA	NA	-3.89%
Vertex Pharmaceuticals Incorporated	BUY	$101.2B	54.04%	28.08	31.86%
Regeneron Pharmaceuticals, Inc.	BUY	$59.4B	2.03%	14.11	31.37%

Stock Returns calculator for Structure Therapeutics, Inc. Stock including INR - Dollar returns

The Structure Therapeutics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Structure Therapeutics, Inc. investment value today

Current value as on today

₹56,290

Returns

₹43,710

(-43.71%)

Returns from Structure Therapeutics, Inc. Stock

₹48,849 (-48.85%)

Dollar Returns*

₹5,139 (+5.14%)

Analyst Recommendation on Structure Therapeutics, Inc. Stock

Based on 14 analysts

BUY

92.86%

Buy

7.14%

Hold

0.00%

Sell

Based on 14 analysts, 92.86% of analysts recommend a 'BUY' rating for Structure Therapeutics, Inc.. Average target price of $73.21

Structure Therapeutics, Inc. Share Price Target

Get share price movements and forecasts by analysts on Structure Therapeutics, Inc..

What analysts predicted

71.47%UPSIDE

Target Price

$73.21

Current Price

$20.89

Analyzed by

14 Analysts

Target

$73.21

Structure Therapeutics, Inc. target price $73.21, a slight upside of 71.47% compared to current price of $20.89. According to 14 analysts rating.

Structure Therapeutics, Inc. Stock's Interest Amongst Investors

Search interest for Structure Therapeutics, Inc. Stock has decreased by -7% in the last 30 days, reflecting a downward trend in search activity.

Time period: August 15, 2025 to September 14, 2025

Change:-7% versus previous 30 day period

Structure Therapeutics, Inc. Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Total Revenue	-	-	-	1	-	-	-	1	-	-
Gross Profit	0	0	0	1	0	0	0	0	0	0
Operating Income	-19	-25	-26	-30	-32	-33	-45	-47	-56	-70
EBITDA	-19	-25	-26	-30	-31	-33	-45	-46	-56	-60
Interest Expense	1	2	2	9	6	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-17	-23	-23	-24	-26	-25	-33	-36	-46	-61
Income Tax Expense	0	0	0	0	0	0	0	0	0	0
Net Income	-17	-23	-23	-24	-26	-26	-33	-36	-46	-61
Net Profit Margin	0.00%	0.00%	0.00%	-1842.38%	0.00%	0.00%	0.00%	-2047.86%	0.00%	0.00%

Structure Therapeutics, Inc. Annual Profit & Loss

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	-	-	-	-	-
Gross Profit	0	0	0	0	-2
Operating Income	0	-37	-52	-102	-158
EBITDA	0	-37	-52	-102	-158
Interest Expense	0	0	1	13	-
Depreciation	-	0	0	0	0
Income Before Tax	0	-37	-51	-89	-122
Income Tax Expense	0	0	0	0	0
Net Income	0	-38	-51	-89	-122
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%

Structure Therapeutics, Inc. Quarterly Cash Flow

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Net Income	-23	-23	-24	-25	-26	-33	-36	-46	-61
Operating Cash Flow	-16	-20	-21	-34	-26	-19	-36	-52	-54
Investing Cash Flow	-68	30	-180	1	-204	-189	33	34	48
Financing Cash Flow	0	0	281	0	514	0	0	0	0
Change in Cash	-85	10	79	-31	283	-209	-2	-17	-5

Structure Therapeutics, Inc. Annual Cash Flow

All numbers in Millions USD

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Net Income	-38	-51	-89	-122
Operating Cash Flow	0	-46	-79	-116
Investing Cash Flow	0	-62	-268	-358
Financing Cash Flow	0	29	451	515
Change in Cash	0	-79	103	39

Insights on Structure Therapeutics, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

NO EFFECT
Against Peers
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 75.7% return, outperforming this stock by 124.8%
NEGATIVE IMPACT
Price Dip
In the last 7 days, GPCR stock has moved down by -5.8%

About Structure Therapeutics, Inc.

Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.

Organisation	Structure Therapeutics, Inc.
Headquarters	601 Gateway Boulevard, South San Francisco, CA, United States, 94080
Industry	Healthcare
CEO	Dr. Raymond C. Stevens Ph.D.
E-voting on shares	Click here to vote

Key Management of Structure Therapeutics, Inc.

Name	Title
Dr. Hui Lei Ph.D.	Senior Vice President of Chemistry
Dr. Raymond C. Stevens Ph.D.	CEO & Director
Dr. Blai Coll M.D., Ph.D.	Chief Medical Officer
Mr. Jun S. Yoon	Co- Founder, CFO & Secretary
Mr. Bob Gatmaitan	Senior Vice President of People
Dr. Fang Zhang Ph.D.	Executive VP & Head of Biology
Ms. Lani Ibarra	Senior Vice President of Clinical Development Operations
Dr. Xichen Lin Ph.D.	Chief Scientific Officer
Dr. Yingli Ma Ph.D.	Chief Technology Officer
Mr. Tony Peng	Senior Vice President of Legal

FAQs

What is Structure Therapeutics, Inc. share price today?

Structure Therapeutics, Inc. share price today is $20.89 as on September 13, 2025 at 1:29 am IST at the close of the market. Structure Therapeutics, Inc. share today touched a day high of $21.47 and a low of $20.29.

What is the 52 week high and 52 week low for Structure Therapeutics, Inc. share?

Structure Therapeutics, Inc. share touched a 52 week high of $45.37 on September 23, 2024 and a 52 week low of $13.22 on April 9, 2025. Structure Therapeutics, Inc. stock price today i.e. September 13, 2025 at 1:29 am IST is closed at $20.89,which is 53.96% down from its 52 week high and 58.02% up from its 52 week low.

What is Structure Therapeutics, Inc.'s market capitalisation today?

Structure Therapeutics, Inc. market capitalisation is $0.00T as on September 13, 2025 at 1:29 am IST.

How to invest in Structure Therapeutics, Inc. Stock (GPCR) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Structure Therapeutics, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Structure Therapeutics, Inc. Shares that will get you 0.0718 shares as per Structure Therapeutics, Inc. share price of $20.89 per share as on September 13, 2025 at 1:29 am IST.

What is the minimum amount required to buy Structure Therapeutics, Inc. Stock (GPCR) from India?

Indian investors can start investing in Structure Therapeutics, Inc. (GPCR) shares with as little as ₹88.27 or $1 (as of September 14, 2025 at 1:38 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹882.70 in Structure Therapeutics, Inc. stock (as per the Rupee-Dollar exchange rate as on September 14, 2025 at 1:38 am IST). Based on Structure Therapeutics, Inc. share’s latest price of $20.89 as on September 13, 2025 at 1:29 am IST, you will get 0.4787 shares of Structure Therapeutics, Inc.. Learn more about fractional shares .